Business
Technology Portfolio Update
Technology Portfolio Update.
About this update from Imaging Biometrics Limited
[{"type":"text","content":"\n \n \n \n RNS Number : 6194L\n IQ-AI Limited\n 14 January 2021\n \n \n \n \n IQ-AI Ltd\n \n \n \n (\"IQ-AI\" or the \"Company\")\n \n \n Technology Portfolio Update\n \n \n \n \n \n In 2020, IQ-AI secured major clients and partners, introduced new products, and accelerated the development of new technologies. Today the Company is pleased to provide an update and an outline of our major plans for 2021. IQ-AI's development pipeline is extensive and growing. \n \n \n Trevor Brown, CEO commented: \"We are operating at a time of rapid innovation where the development and clinical translation of medical AI solutions will provide a paradigm shift in routine clinical practice, resulting in improved patient care. The Company is optimistic that substantial progress will be made in all these initiatives during 2021\". \n \n \n 1. IB Trax™, an entirely new platform initially targeted to assist the assessment of metastatic brain tumours, is being developed in partnership with the Mayo Clinic. The core team, which includes Dr. Leland Hu, MD of the Mayo Clinic (Arizona, USA), has begun translating the desired workflow into software requirements and specifications. The focus is on providing a streamlined workflow to systematically identify, quantify, and organize volumetric analysis for metastatic brain lesions. The Board believes that the initial version of IB Trax will form the foundation for streamlining the assessment of other cancers and pathologies.\n \n \n \n 2. The \"Gad Free\" technology is about to embark on the next round of validation testing which includes subjecting the algorithm to a comprehensive and extensive testing protocol. To accomplish this, a large number of test datasets are being prepared to fully assess the robustness of the technology. Although challenging, the Board considers that this novel solution would be the first in the world and the Company is confident the appropriate technical team is in place to deliver. The patent application submitted in Q4 2018, is advancing through the US Patent and Trademark Office review process. \n \n \n \n 3. Interest continues to increase in the recent FDA-cleared and CE-marked LSN (Liver Surface Nodularity) platform. Prospective users are inquiring about LSN's ability to perform virtual biopsies to help assess chronic liver disease for an ...